Last week the Medicines and Healthcare products Regulatory Agency (MHRA) published guidance regarding the continuity of supply of Investigational Medicinal Products (IMPs) being used in clinical trials in the event of a no-deal Brexit.

The guidance encourages organisations that run clinical trials in the UK to consider their supply chains for IMPs ahead of 29 March 2019 to ensure that possible border delays do not cause disruption to patients and trials.

Back to e-newsletter